GLP-1 RA Cessation and Gastric Ultrasound Findings

NCT07623148 | Recruiting

• 1 other identifier: Wonkwang UH25
• Study Type: observational
• Target: 186
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective observational study will evaluate the association between the time interval since the last dose of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and residual gastric contents before elective surgery. Adult patients receiving GLP-1 RAs and scheduled for elective non-cardiac surgery under general anesthesia will undergo preoperative point-of-care gastric ultrasound. The study will assess whether longer GLP-1 RA cessation intervals are associated with lower ultrasound-estimated gastric volume and a lower frequency of high-risk gastric contents. Body mass index will also be evaluated as a potential modifier of this association.

Conditions

Residual Gastric Contents; Delayed Gastric Emptying

Outcome Measures

Primary Outcomes (1)

• Estimated Gastric Volume Normalized to Body Weight

  Estimated gastric volume normalized to body weight, expressed as mL/kg, calculated from the antral cross-sectional area measured by preoperative point-of-care gastric ultrasound in the right lateral decubitus position.

  Immediately before induction of anesthesia on the day of surgery

Secondary Outcomes (3)

• Antral Cross-Sectional Area

  Immediately before induction of anesthesia on the day of surgery

• Perlas Gastric Ultrasound Grade

  Immediately before induction of anesthesia on the day of surgery

• Gastrointestinal Symptom Score

  Within 24 hours before surgery

Study Arms (3)

Last GLP-1 RA Dose 3 Days or Less

Participants receiving glucagon-like peptide-1 receptor agonists whose last dose was taken 3 days or less before elective surgery. No intervention was assigned by the study protocol; GLP-1 RA management followed usual clinical care. Participants underwent preoperative point-of-care gastric ultrasound to assess residual gastric contents.

Other: GLP-1 RA Cessation Interval

Last GLP-1 RA Dose 4 to 7 Days

Participants receiving glucagon-like peptide-1 receptor agonists whose last dose was taken 4 to 7 days before elective surgery. No intervention was assigned by the study protocol; GLP-1 RA management followed usual clinical care. Participants underwent preoperative point-of-care gastric ultrasound to assess residual gastric contents.

Other: GLP-1 RA Cessation Interval

Last GLP-1 RA Dose 8 Days or More

Participants receiving glucagon-like peptide-1 receptor agonists whose last dose was taken 8 days or more before elective surgery. No intervention was assigned by the study protocol; GLP-1 RA management followed usual clinical care. Participants underwent preoperative point-of-care gastric ultrasound to assess residual gastric contents.

Other: GLP-1 RA Cessation Interval

Interventions

GLP-1 RA Cessation Interval OTHER

Observed exposure defined as the number of days between the participant's last glucagon-like peptide-1 receptor agonist dose and elective surgery. Participants were categorized according to time since last dose: 3 days or less, 4 to 7 days, and 8 days or more. No GLP-1 receptor agonist was assigned, administered, continued, or discontinued by the study protocol; medication management followed usual clinical care.

Also known as: Time Since Last GLP-1 RA Dose, GLP-1 RA Discontinuation Interval

Last GLP-1 RA Dose 3 Days or Less; Last GLP-1 RA Dose 4 to 7 Days; Last GLP-1 RA Dose 8 Days or More

Eligibility Criteria

• Age: 19 Years - 65 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients receiving glucagon-like peptide-1 receptor agonists who are scheduled for elective non-cardiac surgery requiring general anesthesia at a tertiary academic hospital. Participants will be screened consecutively by the perioperative anesthesia team and enrolled if eligibility criteria are met.

You may qualify if:

• Adults aged 18 years or older.
• Patients receiving a glucagon-like peptide-1 receptor agonist.
• Patients scheduled for elective non-cardiac surgery requiring general anesthesia.
• Patients able to provide written informed consent.

You may not qualify if:

• Emergency surgery.
• History of prior gastric surgery.
• Known gastroparesis or severe gastroesophageal reflux disease.
• Declined or unable to provide written informed consent.

Sponsors & Collaborators

• Wonkwang University Hospital: lead

Study Sites (1)

Wonkwang University School of Medicine Hospital

Iksan, Jeonbuk-do, 54538, South Korea

RECRUITING

MeSH Terms

Conditions

Gastroparesis

Condition Hierarchy (Ancestors)

Stomach Diseases; Gastrointestinal Diseases; Digestive System Diseases; Paralysis; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Cheol Lee, M.D.,Ph.D

  Wonkwang University Hosptial

  STUDY DIRECTOR

Central Study Contacts

Cheol Lee, M.D.,Ph.D

CONTACT

+82-63-8591563; ironyii70@gmail.com

Hyungjong Yu, M.D.

CONTACT

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: May 28, 2026
• First Posted: June 3, 2026
• Study Start: July 1, 2026
• Primary Completion: July 20, 2026
• Study Completion (Estimated): August 20, 2026
• Last Updated: July 22, 2026

Record last verified: 2026-07

Locations

KR (1)